Aug 2026· Odontology : official journal of The Society of the Nippon Dental University· 0 citations· 20 references
Medicine
TL;DR
The data suggest that FBLIM1 overexpression is a crucial factor in HNSCC tumorigenesis and may be a promising prognostic biomarker and further mechanistic research and functional studies are needed to assess the therapeutic potential of suppressing FBLIM1 in HNSCC.
It is suggested that DAPK1 is associated with apoptosis-related signaling, increased immune-cell infiltration, and favorable clinical outcomes in OSCC, although its independent prognostic value requires validation in larger cohorts.
It is suggested that abnormal RPL5 expression may be associated with TNBC biology through ribosome-related programs, although causal roles require functional validation.
Bing Zhao, Peiyuan Yu, Li Li et al.· European Journal of Histoche...· 0 citations
CCNE1 overexpression characterises a clinically aggressive subset of breast cancers, particularly TNBC, and targeting mTORC1 may represent a promising therapeutic approach in CCNE1-high, TP53-mutated, and RB1-deficient tumours, supporting the clinical utility of CCNE1 in patient stratification and targeted therapy.
Nigar Pelin Makas, N. Belder, Özge Akbulut-Çalışkan et al.· Clinical and Translational O...· 0 citations
Background/Objectives: Schlafen 11 (SLFN11) encodes a DNA damage response protein implicated in sensitivity to DNA-damaging therapies and has been proposed as a predictive biomarker in several malignancies. This study aimed to characterize SLFN11 expression and evaluate its prognostic and predictive significance in loc...
J. Jelenkovic, Marko Miladinov, Katarina Erić et al.· Biomedicines· 0 citations
OBJECTIVE
To investigate FUBP1 expression, its prognostic value, impact on the tumor microenvironment (TME), and drug sensitivity in colorectal cancer (CRC), and to explore its potential underlying mechanisms.
METHODS
Using data from The Cancer Genome Atlas (TCGA), we analyzed FUBP1 expression in CRC, evaluated its p...
Zhen-Xiang Li, Yan-Fang Zhao, Yan-Li Si et al.· Cancer Treatment and Researc...· 0 citations
While RGS2 is consistently down-regulated at the transcript level in ovarian cancer, it is not significantly associated with patient survival, and its utility as a standalone prognostic biomarker is limited in unstratified transcriptomic analyses.
A. A. Ghifari, M. Sianturi, Suyanto Suyanto et al.· Jurnal Ilmiah Kesehatan· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
